Three autism clinical trial opportunities

ASN

• share
• email
• print

Targeted Pharmacological Interventions for Autism: A Double-Blind, Placebo-Controlled Study of Atomoxetine in Children and Adolescents with Autism

The Massachusetts General Hospital for Children at the Lurie Center is conducting a research study for children and adolescents ages 5-15 who have autistic disorder, Asperger’s disorder, or pervasive developmental disorder, not otherwise specified and who also have symptoms such as: overactivity, impulsivity, and/or inattention. The study involves a non-stimulant medication and clinic visits at no charge. If you would like to find out more about this research study at the Lurie Center, please contact us at (781) 860-1711 or [email protected]. Institution – MGH - Massachusetts General Hospital, Boston, MA; Lurie Center, Lexington, MA. Principle Investigator: Christopher J McDougle, MD

Guanfacine and Methylphenidate in the Treatment of Hyperactivity in Children with Pervasive Developmental Disorder

The Massachusetts General Hospital for Children at the Lurie Center is conducting a Research Study for children 5–14 years old who have Pervasive Developmental Disorders (autism, Asperger’ disorder, or PDD-NOS). If your 5-14 year old has autism, Asperger’ disorder, or PDD-NOS, he or she may qualify for a research study involving study medication and clinic visits with a child psychiatrist and qualified research staff at no charge. The purpose of this study is to find out if the medication, extended release guanfacine, is helpful for the treatment of hyperactivity and impulsiveness in children. Participation requirements and risks involved in this study will be disclosed prior to study enrollment. If you are interested in participating or would like more information, please contact us at (781) 860-1700 or [email protected]. Institution – MGH - Massachusetts General Hospital, Boston, MA; Lurie Center, Lexington, MA. Principle Investigator: Christopher J McDougle, MD

Pervasive Developmental Disorders Research Study

The Massachusetts General Hospital for Children at the Lurie Center is conducting a study designed to evaluate the effects of mirtazapine in children with Pervasive Developmental Disorders (PDDs). Participants must be children between the ages of 5 and 17 with autistic disorder, Asperger’s disorder or PDD not otherwise specified, as well as difficulties with anxiety. Participants must have no significant medical illness and not have had a previous adequate trial of mirtazapine. Participants will receive study medication and all study related evaluations at no charge. For additional information about study requirements and study procedures, please contact Dr. Christopher McDougle’s study staff at 781-860-1711 or [email protected].